Literature DB >> 2362955

Effect of intracerebroventricular and systemic injections of caerulein, a CCK analogue, on electrical self-stimulation and its interaction with the CCKA receptor antagonist, L-364,718 (MK-329).

M H Hamilton1, I C Rose, L J Herberg, J S de Belleroche.   

Abstract

Systemic administration of caerulein (10-100 micrograms/kg SC), a potent analogue of cholecystokinin, caused a profound dose-related depression of variable-interval self-stimulation, followed by progressive recovery within 60 min. Intracerebroventricular injection of caerulein (3-1000 ng) was not more effective than systemic injection, while injections into the nucleus accumbens (3-100 ng bilaterally) were without detectable effect. Systemic injections of L-364,718 (70-700 micrograms/kg IP), a specific competitive antagonist of CCKA ("peripheral-type") receptors, had no effect on self-stimulation when given alone. When given in combination with caerulein, L-364,718 (200 micrograms/kg IP) significantly reduced the inhibitory effect of caerulein (30 micrograms/kg SC); however, this dose, and higher doses of L-364,718, failed to confer complete protection. It is concluded that self-stimulation performance may be subject to modulation by CCK receptors distributed predominantly in the peripheral nervous system and that some but not all of these receptors are CCKA receptors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2362955     DOI: 10.1007/bf02244058

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  25 in total

Review 1.  Catecholamine theories of reward: a critical review.

Authors:  R A Wise
Journal:  Brain Res       Date:  1978-08-25       Impact factor: 3.252

2.  Chronic l-dopa fails to lessen rebound enhancement of self-stimulation after chronic haloperidol.

Authors:  I C Rose; M Mintz; L J Herberg
Journal:  Pharmacol Biochem Behav       Date:  1988-07       Impact factor: 3.533

3.  Neuroleptics and brain self-stimulation behavior.

Authors:  A Wauquier
Journal:  Int Rev Neurobiol       Date:  1979       Impact factor: 3.230

4.  Cholecystokinin potentiates dopamine-mediated behaviors in the nucleus accumbens, a site of CCK-DA co-existence.

Authors:  J N Crawley
Journal:  Psychopharmacol Bull       Date:  1985

5.  The cholecystokinin analogue, caerulein, does not modulate dopamine release or dopamine-induced locomotor activity in the nucleus accumbens of rat.

Authors:  M Hamilton; M J Sheehan; J De Belleroche; L J Herberg
Journal:  Neurosci Lett       Date:  1984-01-27       Impact factor: 3.046

6.  Anti-conflict and depressant effects by GABA agonists and antagonists, benzodiazepines and non-gabergic anticonvulsants on self-stimulation and locomotor activity.

Authors:  L J Herberg; S F Williams
Journal:  Pharmacol Biochem Behav       Date:  1983-10       Impact factor: 3.533

7.  Antagonism of cholecystokinin-like peptides by opioid peptides, morphine or tetrodotoxin.

Authors:  G Zetler
Journal:  Eur J Pharmacol       Date:  1979-11-23       Impact factor: 4.432

8.  Cholecystokinin potentiates the rate-decreasing effects of morphine on schedule-controlled behavior in rats.

Authors:  P J Winsauer; A L Riley
Journal:  Pharmacol Biochem Behav       Date:  1988-07       Impact factor: 3.533

Review 9.  Can drug effects on anxiety and convulsions be separated?

Authors:  S Pellow
Journal:  Neurosci Biobehav Rev       Date:  1985       Impact factor: 8.989

10.  Rapid development of tolerance to the behavioural actions of cholecystokinin.

Authors:  J N Crawley; M C Beinfeld
Journal:  Nature       Date:  1983-04-21       Impact factor: 49.962

View more
  1 in total

1.  Differential involvement of CCK-A and CCK-B receptors in the regulation of locomotor activity in the mouse.

Authors:  E Vasar; J Harro; A Lang; A Pôld; A Soosaar
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.